Apollomics Inc., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-3, filed on May 20, 2024, will not undergo review. The SEC's communication, dated May 24, 2024, was addressed to Sanjeev Redkar, President of Apollomics. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded Apollomics and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. Alan Campbell was designated as the contact person for any further inquiries.

Apollomics Inc., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-3, filed on May 20, 2024, will not undergo review. The SEC's communication, dated May 24, 2024, was addressed to Sanjeev Redkar, President of Apollomics. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded Apollomics and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. Alan Campbell was designated as the contact person for any further inquiries.